Other news to note
Sorrento Therapeutics Inc., of San Diego, obtained exclusive rights to Cynviloq (Genexol-PM) in Australia, Canada and Mexico from Samyang Biopharmaceuticals, of South Korea. Sorrento already has exclusive rights from Samyang in the U.S. and the 27 European Union countries. Cynviloq is a next-generation branded paclitaxel formulation to treat metastatic breast cancer, non-small-cell lung cancer, pancreatic cancer, and other solid tumors.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST